系统综述显示各国孕期RSV疫苗接种率差异明显,美国首年约27%
Global study finds stark differences in maternal RSV vaccine uptake
一项发表于 The Lancet Regional Health - Europe 的系统综述与Meta分析汇总2023至2025年间16项研究、逾400万例妊娠数据,发现各国孕期RSV疫苗接种率差异明显,美国在疫苗可及首年约27%,苏格兰最高达62%,英格兰为58%。
汇总16项研究、逾400万例妊娠数据,对比苏格兰、英格兰与美国等地的接种率差异,并给出安全性监测结果。
Vaccination against a common respiratory virus during pregnancy lowers the risk of severe disease in babies by 74%, but uptake in many countries remains low, a new review suggests. The report also reveals evidence of lower uptake of the respiratory syncytial virus (RSV) vaccine among some socioeconomic and ethnic groups, those with reduced access to health care and younger mothers.
Despite the value of vaccination in preventing hospitalization and deaths in young infants, higher uptake is needed to maximize its benefits, experts say.
The study is published in The Lancet Regional Health - Europe.
The findings demonstrate the need for targeted outreach, improved supply chain systems and robust policies as RSV vaccinations are rolled out globally, they add.
Global rollout, uneven uptake
Vaccination against RSV during pregnancy—known as maternal vaccination—has been shown to give babies protection against the virus from the moment they are born.
More than 30 countries have now introduced the maternal RSV vaccine as either a stand-alone intervention or alongside other preventive measures, such as infant immunization.
Research led by a collaboration between the University of Edinburgh and the University of Granada in Spain combined data from more than 4 million pregnancies between 2023 and 2025, across 16 studies, to estimate the uptake of vaccination programs.
At the time the review was conducted, Scotland's highest coverage rate since the vaccine's introduction in the U.K. in September 2024 was 62% of pregnant women vaccinated in October 2025. England achieved its highest vaccination rate of 58% in August 2025.
The United States had some of the lowest overall uptake, with an estimated 27% vaccinated during the first year the maternal RSV vaccine was available. The vaccine is delivered alongside other preventive interventions.
The research team notes that these figures are lower than those for other maternal vaccines, such as whooping cough, in the same period.
Safety evidence and ongoing monitoring
The report also provides valuable population-level evidence on vaccine safety, with no evidence of an increased risk of preterm birth in those vaccinated at 32–35 weeks of pregnancy, based on data from more than 16,000 pregnancies.
As more countries introduce RSV prevention programs, analyzing the emerging real-world evidence is necessary to monitor the impact of vaccination, support policymakers, health care workers and pregnant individuals, and inform future vaccination campaigns, experts say.
The research team also included colleagues from Public Health Scotland and the Pan American Health Organization (PAHO/WHO), with input from six other universities in the U.K.
Timing and access shape protection
Dr. Ting Shi, from the University of Edinburgh's Usher Institute, said, "We found the vaccine reduced the risk of RSV-related hospitalization in babies under six months by around 74%, which lines up well with what the clinical trials predicted, and we found no evidence of an increased risk of preterm birth. But uptake during the first vaccination seasons was low.
"Timing matters too. The vaccine works best when it's given at least two weeks before birth, so making sure women can access it early in their eligibility window is key. The vaccine itself looks safe and effective—the next challenge is making sure everyone who could benefit actually gets it."
Dr. Evelyn Balsells, University of Granada, said, "Research shows that RSV vaccination during pregnancy protects babies. Efforts to increase uptake and reduce disparities will be essential to maximize the benefits of maternal RSV vaccination."
Dr. Kimberly Marsh, viral respiratory pathogens lead at Public Health Scotland, said, "This review shows that maternal RSV vaccination is protecting babies from severe illness but uptake is not equal across all communities. Monitoring vaccine coverage and addressing barriers faced by some ethnic groups and more deprived communities will be important to ensure that all families can benefit from protection the RSV vaccine offers to babies."
More information
Real-world evidence on maternal RSV vaccination uptake, effectiveness, and safety: a systematic review and meta-analysis, The Lancet Regional Health - Europe (2026).
Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Global study finds stark differences in maternal RSV vaccine uptake (2026, October 7) retrieved 7 October 2026 from https://medicalxpress.com/news/2026-10-global-stark-differences-maternal-rsv.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com